Literature DB >> 10393832

Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation.

H Funato1, M Enya, M Yoshimura, M Morishima-Kawashima, Y Ihara.   

Abstract

The amyloid cascade hypothesis of Alzheimer's disease postulates that accumulation of amyloid beta-protein (Abeta) precedes neurofibrillary tangle formation or neuronal loss in the cortex. Although this temporal profile has been proved in the neocortex by silver staining and immunocytochemical methods, CA1 of the hippocampus exhibits a distinct temporal profile during normal aging: the formation of neurofibrillary tangles precedes senile plaque formation. This temporal profile has been further confirmed by two-site enzyme immunoassay (EIA) quantitation of sodium dodecyl sulfate (SDS)-dissociable Abeta42; neurofibrillary tangles are already present despite undetectable levels of SDS-dissociable Abeta42. However, when the same specimens were subjected to Western blotting, many cases with or without neurofibrillary tangles showed some accumulation of SDS-stable Abeta dimers that cannot be detected by EIA. Thus, the temporal profile prerequisite for the hypothesis is still valid in CA1, and this finding also suggests that SDS-stable Abeta dimers have some significant effects on CA1 pyramidal neurons, which are most vulnerable to neurofibrillary tangle formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393832      PMCID: PMC1866667          DOI: 10.1016/s0002-9440(10)65094-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.

Authors:  M C Irizarry; F Soriano; M McNamara; K J Page; D Schenk; D Games; B T Hyman
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases.

Authors:  M C Tierney; R H Fisher; A J Lewis; M L Zorzitto; W G Snow; D W Reid; P Nieuwstraten
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

4.  Alzheimer's changes in non-demented and demented patients.

Authors:  K A Jellinger
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

5.  Alzheimer's changes in non-demented and demented patients: a statistical approach to their relationships.

Authors:  D Langui; A Probst; J Ulrich
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

6.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

Authors:  A Lorenzo; B A Yankner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

7.  Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease.

Authors:  Y M Kuo; S Webster; M R Emmerling; A E Roher
Journal:  Biochim Biophys Acta       Date:  1998-04-28

8.  beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger.

Authors:  A J Bruce; B Malfroy; M Baudry
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

9.  Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging.

Authors:  M Enya; M Morishima-Kawashima; M Yoshimura; Y Shinkai; K Kusui; K Khan; D Games; D Schenk; S Sugihara; H Yamaguchi; Y Ihara
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

10.  Hydrogen peroxide mediates amyloid beta protein toxicity.

Authors:  C Behl; J B Davis; R Lesley; D Schubert
Journal:  Cell       Date:  1994-06-17       Impact factor: 41.582

View more
  17 in total

1.  Molecular dynamics simulation of amyloid beta dimer formation.

Authors:  B Urbanc; L Cruz; F Ding; D Sammond; S Khare; S V Buldyrev; H E Stanley; N V Dokholyan
Journal:  Biophys J       Date:  2004-10       Impact factor: 4.033

2.  Differential effects of amyloid-β peptide aggregation status on in vivo retinal neurotoxicity.

Authors:  H R Watts; Pjb Anderson; D Ma; K L Philpott; S M Jen; M Croucher; L S Jen; S M Gentleman
Journal:  Eye Brain       Date:  2010-09-09

Review 3.  APP transgenic mice: their use and limitations.

Authors:  Claudia Balducci; Gianluigi Forloni
Journal:  Neuromolecular Med       Date:  2010-12-09       Impact factor: 3.843

4.  The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia.

Authors:  Jessica M Mc Donald; George M Savva; Carol Brayne; Alfred T Welzel; Gill Forster; Ganesh M Shankar; Dennis J Selkoe; Paul G Ince; Dominic M Walsh
Journal:  Brain       Date:  2010-04-19       Impact factor: 13.501

5.  Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types.

Authors:  A K Sian; E R Frears; O M El-Agnaf; B P Patel; M F Manca; G Siligardi; R Hussain; B M Austen
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

6.  Endocytic pathways mediating oligomeric Abeta42 neurotoxicity.

Authors:  Chunjiang Yu; Evelyn Nwabuisi-Heath; Kevin Laxton; Mary Jo Ladu
Journal:  Mol Neurodegener       Date:  2010-05-17       Impact factor: 14.195

7.  The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Authors:  Kerensa Broersen; Frederic Rousseau; Joost Schymkowitz
Journal:  Alzheimers Res Ther       Date:  2010-07-14       Impact factor: 6.982

Review 8.  Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.

Authors:  Dennis J Selkoe
Journal:  Behav Brain Res       Date:  2008-02-17       Impact factor: 3.332

Review 9.  A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Giancarlo Logroscino
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

10.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.